Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. (CST), headquartered in the United States, is a leading provider of innovative research tools in the life sciences industry. Founded in 1999, CST has established itself as a key player in the field of cell signalling, offering a comprehensive range of high-quality antibodies, assays, and reagents that support cutting-edge research in cancer, neuroscience, and immunology. With a commitment to scientific excellence, CST's products are distinguished by their specificity and reliability, making them essential for researchers worldwide. The company has achieved notable milestones, including numerous awards for product innovation and quality, solidifying its position as a trusted partner in the scientific community. Through its dedication to advancing cell signalling research, Cell Signaling Technology continues to empower scientists in their quest for discovery.
DitchCarbon Score
How does Cell Signaling Technology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cell Signaling Technology, Inc.'s score of 46 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cell Signaling Technology, Inc.'s reported carbon emissions
In 2023, Cell Signaling Technology, Inc. reported total carbon emissions of approximately 8,000,000 kg CO2e, comprising 1,115,000 kg CO2e from Scope 1, 2,915,000 kg CO2e from Scope 2, and 4,030,000 kg CO2e from Scope 3 emissions. This reflects a slight decrease in Scope 1 and Scope 3 emissions compared to 2022, where total emissions were about 8,000,000 kg CO2e, with Scope 1 at 1,157,000 kg CO2e, Scope 2 at 2,910,000 kg CO2e, and Scope 3 at 4,067,000 kg CO2e. Cell Signaling Technology has committed to achieving net-zero emissions by 2029, making it the first life science member to set such a target. This commitment encompasses all scopes of emissions, indicating a comprehensive approach to reducing their carbon footprint. The company is actively working towards this goal, with initiatives aimed at reducing emissions across its operations. The emissions data is not cascaded from any parent organization, and all figures are directly reported by Cell Signaling Technology, Inc. As a participant in the pharmaceuticals, biotechnology, and life sciences sector, the company is aligning its climate commitments with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2014 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 3,252,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,154,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 3,393,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cell Signaling Technology, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
